.jpg)
The microbicides field has undoubtedly moved and shifted a lot in the past decade. Now, with first generation microbicides candidate products up and gone, antiretroviral treatment (ART)-drug based microbicides in spotlight, and only three major microbicides efficacy studies remaining, the need to lobby for increased funding of microbicides research and development, was never so compelling.
The need to bolster HIV prevention has certainly not dimmed - and so has the need to up HIV treatment, care and support which is becoming acute on daily basis. The International Microbicides Conference (M2010) opened with the plenary that cited UNAIDS data, from New York Times news (At Front Lines, AIDS War Is Falling Apart), "For every 100 people put on antiretroviral treatment (ART), 250 people are getting newly infected with HIV."
"People were already questioning that whether universal access to treatment is achievable without significantly reducing the number of new infections" said Professor (Dr) Robin Shattock, who is a Professor of Cellular and Molecular Infection in the Department of Cellular and Molecular Medicine at St George's University of London, UK.
"Donors were questioning too whether it is sustainable to continue the roll out of treatment across the globe" said Prof Shattock.
Read more.
Listen to the audio podcast of Prof Robin Shattock, courtesy of IRMA pal Bobby Ramakant.
No comments:
Post a Comment